Five insiders -- Sachdev, Silva, Dr Altshuler, Arbuckle, and Parini -- today, sold 25,896 shares of Vertex Pharmaceuticals having a market value of...
Five insiders -- Sachdev, Silva, Dr Altshuler, Arbuckle, and Parini -- today, disposed of 25,896 shares of Vertex Pharmaceuticals having a market value of...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
SEC filings today reported notable insider sales of Vertex Pharmaceuticals shares as five insiders -- Sachdev, Silva, Dr Altshuler, Arbuckle, and Parini --...
| Address | 50 Northern Avenue Boston, Massachusetts 02210 |
| Phone | +1.617.341.6100 |
| Number of Employees | 2,500 |
| Recent SEC Filing | 02/26/2021 4 |
| President, Chief Executive Officer & Director | Reshma Kewalramani |
| Chief Financial Officer & Executive Vice President | Charles F. Wagner |
| Chief Scientific Officer & EVP-Global Research | David Matthew Altshuler |
| Senior VP, Chief Information & Data Officer | Mike Tirozzi |
| Price Open | $212.68 |
| Previous Close | $212.55 |
| 52 Week Range | $197.47 - 306.08 |
| Market Capitalization | $54.7 B |
| Shares Outstanding | 260.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 05/05/2021 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 20.64 |
| Earnings per Share | $9.81 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.0 B |
| Net Profit Margin | 43.67% |
| Return on Equity | 35.21% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
